# UK Drug Repurposing Market > UK Drug Repurposing Market Research Report: Size, Share, Trend Analysis By Typess (Disease-centric, Target-centric, Drug-centric), By Therapeutic Area (Same Therapeutic Area, Different Therapeutic Area) and By Drug Molecules (Biologics, Small Molecule) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 15.03% - **2024:** $ 15 Million - **2025:** $ 17.25 Million - **2035:** $ 70 Million - **Key Players:** Pfizer Inc (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), AstraZeneca PLC (GB), Eli Lilly and Company (US), Gilead Sciences Inc (US), Amgen Inc (US) **Report ID:** MRFR/Pharma/50631-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-drug-repurposing-market-52389 --- ## Market Summary ## **UK Drug Repurposing Market Overview** As per MRFR analysis, the UK Drug Repurposing Market Size was estimated at 11.25 (USD Million) in 2023. The UK Drug Repurposing Market Industry is expected to grow from 12.68(USD Million) in 2024 to 53.34 (USD Million) by 2035. The UK Drug Repurposing Market CAGR (growth rate) is expected to be around 13.955% during the forecast period (2025 - 2035) ### **Key UK Drug Repurposing Market Trends Highlighted** The UK Drug Repurposing Market is experiencing a significant shift driven by various key market drivers. One of the primary drivers is the increasing pressure to reduce drug development costs and timelines, which is critical in a healthcare system like the NHS that continually seeks cost-effective solutions. The growing incidence of emerging diseases and the looming threat of antibiotic resistance further fuel the demand for repurposing existing drugs, as it often offers faster and more economical treatment options compared to developing new drugs from scratch.  Moreover, the supportive regulatory environment in the UK, which encourages innovation and expedites approvals for repurposed drugs, enhances the attractiveness of this market.Opportunities abound in the UK market, particularly in therapeutic areas such as oncology, where existing drugs can be rapidly evaluated for new applications. Targeting the prevalence of chronic diseases such as diabetes and cardiovascular conditions also presents a promising avenue for repurposing efforts.  Furthermore, collaboration between academic institutions and pharmaceutical companies can lead to breakthroughs in identifying new uses for established medications, leveraging the UK’s strong research capabilities in drug development. In recent times, there has been a notable trend towards utilizing digital health technologies and real-world evidence to support drug repurposing initiatives.With the rise of electronic health records and patient registries, UK researchers are gaining access to vast datasets that enable better identification of potential drug repurposing candidates.  Additionally, the COVID-19 pandemic has catalyzed interest in leveraging existing drugs to combat new health challenges, resulting in a surge of studies focused on drug repurposing in the UK. This trend not only addresses immediate healthcare needs but also lays the groundwork for a more resilient healthcare framework in the future. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **UK Drug Repurposing Market Drivers** ### **Growing Prevalence of Chronic Diseases** One of the main factors propelling the UK drug repurposing market industry is the rising incidence of chronic illnesses, especially among the country's aging population. Approximately one in four people in the UK, or 15 million people, live with a chronic disease, according to the National Health Service (NHS). Drug repurposing activities have increased as a result of this expanding quantity, which suggests a growing need for efficient therapies.  GlaxoSmithKline and other pharmaceutical firms have recognized the need for creative ways to effectively treat these illnesses. Repurposing current medications might hasten the release of reasonably priced therapies, which makes it a practical tactic, particularly in light of growing healthcare expenses. Unlocking the potential of current pharmaceuticals through research and development programs becomes crucial as the UK government concentrates on enhancing healthcare access, which will contribute to market growth. ### **Advancements in Research and Development** Recent advancements in Research and Development (R&D) technologies and methodologies have significantly impacted the UK Drug Repurposing Market Industry. The UK government has devoted substantial funding to innovative research programs, as evidenced by the UK Research and Innovation (UKRI) initiative, which allocated 8 billion to support research efforts in recent years.  This influx of capital enables academic institutions and biotechnology firms to explore novel drug applications, leading to an increased number of drug repurposing projects.By harnessing advanced data analytics and machine learning, researchers can identify potential new uses for existing drugs, enhancing the chances of successful market entry. The collaborative work between universities, such as University College London, and hospitals is enhancing the R&D landscape, further driving the growth of the market. ### **Supportive Government Policies and Regulations** Supportive government policies and regulatory frameworks in the UK act as significant catalysts for the UK Drug Repurposing Market Industry. Initiatives like the Accelerated Access Collaborative and the Medicines and Healthcare products Regulatory Agency (MHRA) encourage faster access to medicines, including repurposed drugs, which substantially reduces time-to-market. According to the MHRA, they aim to reduce the time it takes to assess new medications by up to 75%. This streamlined approach fosters a conducive environment for pharmaceutical companies and researchers to invest in drug repurposing, ultimately leading to a more dynamic marketplace. The UK government’s commitment to enhancing public health outcomes reinforces the strategic focus on repurposing as not only an alternative path for treatment but also a vital component of the national healthcare strategy. ## **UK Drug Repurposing Market Segment Insights** ### **Drug Repurposing Market Types Insights** The UK Drug Repurposing Market is evolving, focusing on innovative strategies that leverage existing drugs for new therapeutic uses. This market segment is primarily categorized into Disease-centric, Target-centric, and Drug-centric approaches, each representing a unique aspect of drug repurposing. Disease-centric strategies prioritize specific medical conditions, aiming to repurpose existing drugs originally developed for different diseases. This approach is particularly significant as it accelerates the availability of treatments for conditions with unmet clinical need, thereby improving patient outcomes in the UK healthcare landscape. Target-centric methods, on the other hand, emphasize the biological targets of the drugs, focusing on how these can be modulated for new therapeutic effects. This approach can lead to more personalized medicine, addressing the need for tailored therapies that match patients' unique genetic profiles. Lastly, Drug-centric methods analyze and repurpose existing drugs based on their chemical properties and pharmacodynamics for different indications, enhancing the existing treatment options available to healthcare providers.  The interplay of these categories underlines a transformative trend in the UK Drug Repurposing Market, supported by a growing body of evidence from clinical trials and research initiatives that highlight the potential of repurposed drugs to address both common and rare diseases.As the regulatory frameworks in the UK continue to adapt, fostering innovation within the pharmaceutical sector, the evolving landscape of Drug Repurposing not only promises expanded treatment possibilities but also offers an economically efficient route to combatting public health challenges.  In summary, the Drug Repurposing Market in the UK is poised for significant growth, with each segment contributing uniquely to the overall landscape and responding to the country’s healthcare demands. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Drug Repurposing Market Therapeutic Area Insights** The Therapeutic Area segment of the UK Drug Repurposing Market showcases a dynamic landscape driven by the need for cost-effective and expedited treatment solutions. With a focus on the Same Therapeutic Area approach, this segment addresses the challenge of leveraging existing drugs for new applications within their original domains. This method not only enhances the therapeutic potential of established medications but also reduces the time and costs associated with traditional drug development. Conversely, the Different Therapeutic Area focus opens up avenues for innovative treatment strategies by applying existing therapies to entirely new disease states. This dual approach is particularly significant in the UK's healthcare system, where there is a strong emphasis on maximizing healthcare efficiency and patient outcomes. The market landscape is further bolstered by favorable government policies that support research initiatives and encourage collaboration between academia and industry, positioning the UK as a leader in drug repurposing efforts. With growing demand to interpret existing compounds in novel ways, addressing unmet medical needs, both segments are poised to play a critical role in transforming therapeutic strategies and improving patient care across the UK. ### **Drug Repurposing Market Drug Molecules Insights** The Drug Molecules segment plays a crucial role in the UK Drug Repurposing Market, reflecting the innovative shifts toward repurposing existing therapies for new therapeutic indications. This approach has gained traction due to its ability to cut down Research and Development time and costs while enhancing treatment options for patients facing various health challenges. Within this segment, Biologics have shown significant promise, offering targeted therapies that leverage biological processes, potentially leading to better outcomes in complex diseases such as cancers and autoimmune disorders. On the other hand, Small Molecules represent a dominant share of the market, known for their versatility and efficacy, particularly in treating chronic conditions. With robust advancements in scientific research, the Drug Molecules segment is poised to capitalize on emerging trends such as personalized medicine. Furthermore, the UK healthcare landscape actively supports these transitions, as initiatives aimed at accelerating drug approvals encourage the exploration of drug repurposing, showcasing a commitment to enhancing patient care and optimizing healthcare resources. The dynamic nature of this segment, influenced by regulatory frameworks and collaborative efforts within the industry, bodes well for its growth trajectory within the broader UK Drug Repurposing Market. ## **UK Drug Repurposing Market Key Players and Competitive Insights** The UK Drug Repurposing Market is rapidly evolving as researchers and pharmaceutical companies strive to find innovative solutions to address unmet medical needs. By leveraging existing drugs for new therapeutic uses, stakeholders can reduce development costs and timelines while achieving regulatory approvals more efficiently than entirely new compounds. The competitive landscape is characterized by a blend of large multinational corporations and smaller biotech firms, all vying for their share of a market that promises both financial returns and significant advancements in patient care.  The sector's growth is driven by increasing collaborations between academia and industry, investments in advanced technologies, and a stronger emphasis from regulatory agencies on expedited review processes for repurposed drugs. AstraZeneca stands as a formidable player in the UK Drug Repurposing Market, utilizing its strong research and development capabilities to explore new therapeutic applications for its existing portfolio. The company's commitment to innovation and drug development is amplified by a robust pipeline of repurposed drugs, particularly in oncology and respiratory diseases. AstraZeneca not only benefits from its solid reputation and established market presence in the UK but also relies on strategic partnerships and collaborations with academic institutions and healthcare organizations. This enhances its ability to effectively identify and validate promising new indications for its existing medications.  AstraZeneca's extensive experience in clinical trials enables it to efficiently move repurposed drugs through the development process while addressing various health challenges in the UK.Roche has also established itself as a key participant in the UK Drug Repurposing Market, focusing on targeted therapies often used in cancer treatment, autoimmune disorders, and other critical health conditions. The company's strengths lie in its comprehensive portfolio of innovative diagnostics and therapeutics, which allows Roche to better understand and cater to patient needs. Key products include targeted therapies that have shown potential for repurposing in other indications.  Roche enhances its market foothold through strategic mergers and acquisitions, which strengthen its research capabilities and expand its existing product offerings. Its emphasis on biotechnology and personalized medicine ensures that Roche remains at the forefront of drug repurposing initiatives in the UK, contributing to the development of solutions that are not only cost-effective but also address pressing health challenges faced by the population. ### **Key Companies in the UK Drug Repurposing Market Include** ## **UK Drug Repurposing Market Industry Developments** Recent developments in the UK Drug Repurposing Market have seen significant activity, particularly among major pharmaceutical companies such as AstraZeneca, Roche, and GlaxoSmithKline. In September 2023, AstraZeneca announced a collaboration with a UK-based biotechnology firm to explore new applications for existing drugs in treating rare diseases, demonstrating a growing interest in the repurposing approach within the sector. Additionally, Roche has ramped up its Research and Development investments focused on leveraging existing therapies for new indications, aiming to address unmet medical needs in oncology.Merger and acquisition trends have also shaped the landscape, with Merck acquiring a smaller biotech firm in August 2023 to enhance its repurposing pipeline.  The growth in market valuation for companies like Pfizer and Johnson and Johnson, particularly in the context of their ongoing research into leveraging existing drugs for conditions like Alzheimer’s and COVID-19, signals a robust interest and potential profitability in the repurposing strategy. Over the past two years, various pharmaceutical companies, including Amgen and Bristol Myers Squibb, have consistently explored drug repurposing, resulting in clinical trials and partnerships that continuously reshape the UK drug market landscape. ## **UK Drug Repurposing Market Segmentation Insights** ## Market Drivers ### Rising Healthcare Costs The escalating costs associated with healthcare in the UK are driving interest in the drug repurposing market. As the National Health Service (NHS) faces budget constraints, there is a pressing need for cost-effective treatment options. Drug repurposing offers a viable solution, as it can significantly reduce the time and financial investment required for drug development. By utilizing existing drugs for new therapeutic indications, the drug repurposing market can potentially lower the average cost of bringing a new treatment to market, which can exceed £1 billion. This financial incentive is likely to encourage pharmaceutical companies and healthcare providers to explore repurposed drugs as a means to alleviate the burden of rising healthcare expenses. ### Advancements in Data Analytics The emergence of advanced data analytics tools is transforming the drug repurposing market in the UK. These tools enable researchers to analyze vast datasets, identifying potential new uses for existing drugs more efficiently. By leveraging machine learning and artificial intelligence, researchers can uncover novel therapeutic applications that may have previously gone unnoticed. This technological advancement is likely to enhance the drug repurposing process, making it more efficient and cost-effective. As a result, the drug repurposing market may experience accelerated growth, as companies harness these innovations to bring repurposed drugs to market more rapidly. ### Supportive Regulatory Environment The regulatory landscape in the UK is becoming increasingly supportive of drug repurposing initiatives. Regulatory bodies, such as the Medicines and Healthcare products Regulatory Agency (MHRA), are recognizing the value of repurposed drugs in addressing public health challenges. This supportive environment is likely to facilitate faster approval processes and streamlined pathways for repurposed drugs, thereby enhancing their market viability. The drug repurposing market benefits from this trend, as it can lead to quicker access to innovative therapies for patients. The potential for reduced regulatory hurdles may encourage more companies to invest in drug repurposing projects, further driving market expansion. ### Collaboration Between Academia and Industry There is a notable trend of collaboration between academic institutions and the pharmaceutical industry in the UK, particularly in the drug repurposing market. These partnerships are fostering innovation and facilitating the sharing of knowledge and resources. Academic researchers often possess valuable insights into drug mechanisms and potential new applications, while industry partners bring expertise in drug development and commercialization. This synergy is likely to enhance the drug repurposing process, leading to the identification of new therapeutic uses for existing drugs. As these collaborations continue to grow, the drug repurposing market may benefit from increased investment and a more robust pipeline of repurposed therapies. ### Increased Patient Demand for Innovative Therapies There is a growing demand among patients in the UK for innovative therapies that can address unmet medical needs. The drug repurposing market is well-positioned to meet this demand, as it allows for the rapid introduction of new treatment options based on existing medications. Patients are increasingly seeking alternatives to traditional therapies, particularly for chronic and complex conditions. This shift in patient expectations is likely to drive investment in the drug repurposing market, as healthcare providers and pharmaceutical companies aim to deliver effective solutions that resonate with patient needs. Improved patient outcomes through repurposed drugs may further stimulate market growth. ## Future Outlook The [Drug Repurposing Market](https://www.marketresearchfuture.com/reports/drug-repurposing-market-22086) is projected to grow at a 15.03% CAGR from 2025 to 2035, driven by technological advancements, regulatory support, and increasing healthcare costs. **New opportunities:** - Development of AI-driven drug screening platforms Partnerships with biotech firms for clinical trials Expansion into personalized medicine applications By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Disease-centric (Largest) vs. Target-centric (Fastest-Growing) In the UK drug repurposing market, the distribution among segment values reveals Disease-centric approaches dominating the landscape. This segment capitalizes on existing drug effectiveness for various diseases, leveraging historical data and clinical experiences. Following closely, the Target-centric approach is gaining traction, focusing on specific biological targets which fosters innovative treatments and broader therapeutic applications. Simultaneously, the Drug-centric segment remains relevant, although it holds a minor share compared to the other two. Disease-centric: Dominant vs. Target-centric: Emerging The Disease-centric segment has established itself as the dominant player in the UK drug repurposing market, primarily due to its established methodology and familiarity within the pharmaceutical community. This approach allows for quicker identification of potential uses for existing drugs, emphasizing patient-centric strategies and optimizing resource allocation. Conversely, the Target-centric segment is emerging as a pivotal player by emphasizing precision medicine and simultaneous targeting of multiple pathways. This robust innovation provides an adaptive and flexible framework to meet evolving healthcare challenges, potentially reshaping treatment paradigms across a spectrum of diseases. ### By Therapeutic Area: Same Therapeutic Area (Largest) vs. Different Therapeutic Area (Fastest-Growing) In the UK drug repurposing market, there is a clear preference for the Same Therapeutic Area, which has carved out the largest share. This preference is due to its familiarity and established protocols in clinical applications. This segment benefits from existing market dynamics and regulatory frameworks that promote further exploration of therapies within the same therapeutic background, driving significant utilization among healthcare professionals. Conversely, the Different Therapeutic Area segment is recognized as the fastest-growing, fueled by innovative research and a push towards solving unmet medical needs. The increasing collaboration among biopharmaceutical companies and academic institutions in exploring new uses for existing drugs is driving this growth. Factors such as the need for cost-effective treatments and the leveraging of advanced technologies are enhancing the potential of this segment. Therapeutic Area: Same vs. Different (Dominant vs. Emerging) The Same Therapeutic Area segment stands out as the dominant player in the UK drug repurposing market, benefiting from its leverage of existing therapeutic knowledge to repurpose drugs effectively. This segment typically involves minimal risk and provides a quicker path to market acceptance as practitioners are accustomed to these therapies. On the other hand, the Different Therapeutic Area segment is emerging rapidly, with increasing attention from researchers looking to repurpose drugs for new indications. This shift is primarily driven by the increasing demand for personalized medicine and the rising costs of drug development, prompting a reevaluation of existing treatments for novel applications. ### By Drug Molecules: Biologics (Largest) vs. Small Molecule (Fastest-Growing) In the UK drug repurposing market, the distribution of market share between biologics and small molecules is distinct. Biologics hold the largest share owing to their complexity and efficacy in treating various diseases, driving significant interest from researchers and pharmaceutical companies. Conversely, small molecules are gaining traction and represent a growing segment of the market as advancements in synthetic biology and medicinal chemistry enhance their development and application. The growth trends in this segment are influenced by several factors, including increasing availability of clinical data supporting repurposing initiatives and advancements in biopharmaceutical technologies. The shift towards personalized medicine and the need for innovative therapeutic solutions are also propelling both biologics and small molecules as vital components for addressing unmet medical needs. The emphasis on cost-effectiveness and rapid deployment in drug development further accentuates the importance of small molecules in the market. Biologics (Dominant) vs. Small Molecule (Emerging) Biologics dominate the UK drug repurposing market due to their ability to target specific biological pathways, making them effective for complex diseases with significant therapeutic potential. Their sophisticated manufacturing processes and high efficacy rates have led to substantial investment in research and development. In contrast, small molecules are emerging as crucial players in this landscape, characterized by lower production costs and quicker development timelines. Their versatility in drug formulation allows for innovative applications and adaptation to various therapeutic areas. As regulators and healthcare providers increasingly favor drugs that combine efficacy with cost-effectiveness, small molecules are positioned to carve out a more significant market share, complementing the established dominance of biologics. ## Competitive Benchmarking The [drug repurposing market](https://www.marketresearchfuture.com/reports/drug-repurposing-market-22086) in the UK is characterized by a dynamic competitive landscape, driven by the need for cost-effective therapeutic solutions and accelerated drug development timelines. Major players such as AstraZeneca PLC (GB), Pfizer Inc (US), and Novartis AG (CH) are strategically positioned to leverage their extensive research capabilities and established market presence. AstraZeneca PLC (GB) focuses on innovative partnerships and collaborations, particularly in oncology and respiratory diseases, which enhances its portfolio through repurposed drugs. Pfizer Inc (US) emphasizes digital transformation and data analytics to streamline its drug repurposing efforts, while Novartis AG (CH) is actively pursuing mergers and acquisitions to bolster its pipeline with repurposed therapies, thereby shaping a competitive environment that prioritizes innovation and strategic alliances.The market structure appears moderately fragmented, with a blend of large pharmaceutical companies and smaller biotech firms. Key players are adopting various business tactics, such as localizing manufacturing and optimizing supply chains, to enhance operational efficiency and reduce costs. This collective influence of major companies fosters a competitive atmosphere where agility and responsiveness to market demands are crucial for success. In October AstraZeneca PLC (GB) announced a collaboration with a leading academic institution to explore the repurposing of existing drugs for the treatment of rare genetic disorders. This strategic move not only diversifies AstraZeneca's therapeutic offerings but also underscores its commitment to addressing unmet medical needs through innovative research. The partnership is expected to accelerate the development timeline for new indications, thereby enhancing AstraZeneca's competitive edge in the market. In September Pfizer Inc (US) launched a new initiative aimed at utilizing artificial intelligence (AI) to identify potential candidates for drug repurposing. This initiative is significant as it positions Pfizer at the forefront of technological integration in drug development, potentially leading to faster identification of viable therapies. The use of AI could streamline the repurposing process, allowing Pfizer to respond more swiftly to emerging health challenges and market opportunities. In August Novartis AG (CH) completed the acquisition of a biotech firm specializing in drug repurposing technologies. This acquisition is pivotal as it enhances Novartis's capabilities in identifying and developing new uses for existing drugs, thereby expanding its therapeutic portfolio. The integration of advanced technologies from the acquired firm is likely to bolster Novartis's competitive positioning in the market, enabling it to deliver innovative solutions more efficiently. As of November current trends in the drug repurposing market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering collaboration that enhances research capabilities and accelerates drug development. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies approach drug repurposing, emphasizing the importance of agility and responsiveness in a rapidly changing market. ## Recent News & Developments Recent developments in the UK Drug Repurposing Market have seen significant activity, particularly among major pharmaceutical companies such as AstraZeneca, Roche, and GlaxoSmithKline. In September 2023, AstraZeneca announced a collaboration with a UK-based biotechnology firm to explore new applications for existing drugs in treating rare diseases, demonstrating a growing interest in the repurposing approach within the sector. Additionally, Roche has ramped up its Research and Development investments focused on leveraging existing therapies for new indications, aiming to address unmet medical needs in oncology.Merger and acquisition trends have also shaped the landscape, with Merck acquiring a smaller biotech firm in August 2023 to enhance its repurposing pipeline.  The growth in market valuation for companies like Pfizer and Johnson and Johnson, particularly in the context of their ongoing research into leveraging existing drugs for conditions like Alzheimer’s and COVID-19, signals a robust interest and potential profitability in the repurposing strategy. Over the past two years, various pharmaceutical companies, including Amgen and Bristol Myers Squibb, have consistently explored drug repurposing, resulting in clinical trials and partnerships that continuously reshape the UK drug market landscape. ## Report Scope | MARKET SIZE 2024 | 15.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 17.25(USD Million) | | MARKET SIZE 2035 | 70.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.03% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer Inc (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), AstraZeneca PLC (GB), Eli Lilly and Company (US), Gilead Sciences Inc (US), Amgen Inc (US) | | Segments Covered | Type, Therapeutic Area, Drug Molecules | | Key Market Opportunities | Emerging technologies enhance drug repurposing efficiency, addressing unmet medical needs and regulatory challenges. | | Key Market Dynamics | Growing emphasis on regulatory compliance drives innovation in the drug repurposing market, enhancing competitive dynamics. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What is the current valuation of the UK drug repurposing market?** A: The market valuation was $15.0 Million in 2024. **Q: What is the projected market size for the UK drug repurposing market by 2035?** A: The projected valuation for 2035 is $70.0 Million. **Q: What is the expected CAGR for the UK drug repurposing market during 2025 - 2035?** A: The expected CAGR is 15.03% during the forecast period. **Q: Which companies are the key players in the UK drug repurposing market?** A: Key players include Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc, and Amgen Inc. **Q: What are the main segments of the UK drug repurposing market?** A: The main segments include Type, Therapeutic Area, and Drug Molecules. **Q: How did the Disease-centric segment perform in 2024?** A: The Disease-centric segment was valued at $5.0 Million in 2024. **Q: What is the valuation of the Small Molecule segment in the UK drug repurposing market?** A: The Small Molecule segment is valued at $10.0 Million. **Q: What is the valuation range for the Different Therapeutic Area segment?** A: The Different Therapeutic Area segment ranges from $4.5 Million to $21.5 Million. **Q: How does the valuation of Biologics compare to Small Molecules in 2024?** A: Biologics were valued at $5.0 Million, while Small Molecules were valued at $10.0 Million. **Q: What is the expected growth trend for the UK drug repurposing market?** A: The market is likely to experience substantial growth, reaching $70.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-drug-repurposing-market-52389*